Inventiva Stock

Inventiva EBIT

The EBIT of Inventiva (IVA.PA) as of Jul 27, 2026 is -136.33 M EUR. In the previous year, EBIT was -97.56 M EUR — a change of 39.74% (lower).

EBIT

-136.33 MEUR

YoY

39.74%

Last updated:

In 2026, Inventiva's EBIT was -136.33 M EUR, a 39.74% increase from the -97.56 M EUR EBIT recorded in the previous year.

The Inventiva EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT (M EUR)
Date
EBIT (M EUR)
Jan 1, 2023
-105.59 base
Jan 1, 2024
-97.56 base
Jan 1, 2025
-136.33 base
Jan 1, 2026 (e)
-120.42 base
Jan 1, 2027 (e)
-129.29 base
Jan 1, 2028 (e)
-75.45 base
Jan 1, 2029 (e)
53.83 base
Jan 1, 2030 (e)
301.58 base
YEAREBIT (M EUR)
2030 est 301.58
2029 est 53.83
2028 est -75.45
2027 est -129.29
2026 est -120.42
2025 -136.33
2024 -97.56
2023 -105.59
2022 -57.11
2021 -52.11
2020 -29.72
2019 -30.31
2018 -33.27
2017 -20.92
2016 -13.02
2015 -15.51
2014 -13.47
2013 -12.47
Access this data via the Eulerpool API

Inventiva Revenue

Inventiva Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
17.48 M EUR
-105.59 M EUR
-110.43 M EUR
Jan 1, 2024
14.72 M EUR
-97.56 M EUR
-184.21 M EUR
Jan 1, 2025
4.48 M EUR
-136.33 M EUR
-354.14 M EUR
Jan 1, 2026 (e)
6.73 M EUR
-120.42 M EUR
-42.68 M EUR
Jan 1, 2027 (e)
108.56 M EUR
-129.29 M EUR
-47.55 M EUR
Jan 1, 2028 (e)
111.52 M EUR
-75.45 M EUR
7.67 M EUR
Jan 1, 2029 (e)
263.75 M EUR
53.83 M EUR
78.17 M EUR
Jan 1, 2030 (e)
475.22 M EUR
301.58 M EUR
256.35 M EUR

Inventiva Margins

Inventiva stock margins

The Inventiva margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Inventiva. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Inventiva.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2023
100.13 %
-604.14 %
-631.84 %
Jan 1, 2024
62.47 %
-662.58 %
-1,251.10 %
Jan 1, 2025
35.07 %
-3,040.98 %
-7,899.58 %
Jan 1, 2026 (e)
35.07 %
-1,788.63 %
-633.98 %
Jan 1, 2027 (e)
35.07 %
-119.10 %
-43.80 %
Jan 1, 2028 (e)
35.07 %
-67.66 %
6.88 %
Jan 1, 2029 (e)
35.07 %
20.41 %
29.64 %
Jan 1, 2030 (e)
35.07 %
63.46 %
53.94 %

Inventiva Stock analysis

What does Inventiva do? Inventiva SA is a biopharmaceutical company based in France that specializes in the development of novel therapies for various diseases. The company was founded in 2002 by Pierre Broqua and Frédéric Cren to develop innovative drugs based on research on the human genome. Inventiva's business model is to develop a pipeline of drug candidates and either sell them or bring them into partnerships with other companies. The company has built a broad portfolio of patents and license agreements that allow it to develop a variety of products. Inventiva's research and development focuses on three key areas: fibrosis, oncology, and autoimmune diseases. In these areas, the company has several product candidates in various stages of clinical development. Inventiva's products include Lanifibranor, a drug for the treatment of fatty liver disease, which is currently in Phase III trials. Additionally, the company has several compounds in its oncology pipeline, including IVA337, IVA336, and IVA339, all of which have shown promising results in preclinical studies. In the field of autoimmune diseases, Inventiva is working on a compound called ABBV-157, which is being developed in collaboration with Abbvie. This compound is intended to help reduce inflammation in patients with rheumatoid arthritis and psoriasis. Overall, Inventiva has made significant progress in recent years and has achieved important milestones in the development of its products. The company has also entered into several partnerships with major pharmaceutical and biotech companies to bring its products to market. In 2020, Inventiva took the next important step in its growth strategy by announcing a merger with American company AbbVie. The acquisition is expected to accelerate the development and commercialization of Inventiva's products and provide the company with a strong partner in the international market. However, Inventiva has not limited itself to drug development. The company has also developed a range of services to support other companies in the development of new drugs. These include laboratory services, protein purification and analysis, cell culture, and more, offered through their own contract research organization (CRO) unit. In summary, Inventiva is an emerging company with a strong portfolio of products and services. The company has done excellent work in developing new medical technologies in recent years and is likely to have even more success in the future with the acquisition by AbbVie. Inventiva is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing Inventiva's EBIT

Inventiva's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Inventiva's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Inventiva's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Inventiva’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Inventiva stock

EBIT of Inventiva is -136.33 M EUR in 2026.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

Income Statement — Inventiva

All Key Metrics — Inventiva